Statin Effects to Reduce Hepatosteatosis as Measured by Computed Tomography in Patients With Human Immunodeficiency Virus

Open Forum Infect Dis. 2016 Jun 13;3(2):ofw062. doi: 10.1093/ofid/ofw062. eCollection 2016 Apr.

Abstract

Hepatosteatosis is highly prevalent among patients living with human immunodeficiency virus. In a 1-year, randomized, double-blind trial of atorvastatin or placebo, atorvastatin increased liver/spleen ratio among patients with nonalcoholic fatty liver disease, indicating a reduction in hepatosteatosis. This reduction in hepatosteatosis is associated with reduction in low-density lipoprotein cholesterol with statin therapy.

Keywords: LDL cholesterol; hepatosteatosis; human immunodeficiency virus; statin.